BioSpace

Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.

By BioSpace

1 min read
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights